scholarly journals Comparative efficacy and tolerance of intralymphatic, subcutaneous and sublingual immunotherapy for pollen-induced allergic rhinitis: a network meta-analysis

2022 ◽  
Author(s):  
Ru Chen ◽  
◽  
Yao Sun ◽  
Guoqi Sima
Keyword(s):  
Allergic Rhinitis ◽  
Sublingual Immunotherapy ◽  
Meta Analysis ◽  
Comparative Efficacy ◽  
Intralymphatic Immunotherapy ◽  
Review Question ◽  
New Type

Review question / Objective: What is the effect of intralymphatic, subcutaneous and sublingual immunotherapy for pollen-induced allergic rhinitis. Condition being studied: Immunotherapy is the classic treatment for allergic rhinitis. Intralymphatic immunotherapy is a new type of treatment. Currently, no studies have compared subcutaneous, sublingual and intralymphatic sublingual immunotherapy. At present, there is no review to compare the efficacy of intralymphatic, subcutaneous and sublingual immunotherapy for pollen-induced allergic rhinitis.

scholarly journals Efficacy and safety of intralymphatic immunotherapy in allergic rhinitis: A systematic review and meta‐analysis

2021 ◽  
Vol 11 (6) ◽  
Author(s):  
Nor Rahimah Aini ◽  
Norhayati Noor ◽  
Mohd Khairi Md Daud ◽  
Sarah K. Wise ◽  
Baharudin Abdullah
Keyword(s):  
Systematic Review ◽  
Allergic Rhinitis ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Intralymphatic Immunotherapy

Intralymphatic immunotherapy for allergic rhinitis: A systematic review and meta-analysis

2021 ◽  
Vol 42 (4) ◽  
pp. 283-292 ◽  
Author(s):  
Michael T. Werner ◽  
John V. Bosso
Keyword(s):  
Systematic Review ◽  
Allergic Rhinitis ◽  
Adverse Event ◽  
Skin Prick Testing ◽  
Meta Analysis ◽  
Mean Difference ◽  
Random Effects Model ◽  
Nasal Provocation ◽  
Intralymphatic Immunotherapy ◽  
Standardized Mean Difference

Background: Only a fraction of patients with allergic rhinitis receive allergen-specific immunotherapy (AIT). AIT is most commonly delivered subcutaneously in a series of injections over 3‐5 years. Common obstacles to completing this therapy include cost and inconvenience. Intralymphatic immunotherapy (ILIT) has been proposed as a faster alternative, which requires as few as three injections spaced 4 weeks apart. Objective: This systematic review and meta-analysis evaluated the current evidence that supports the use of ILIT for allergic rhinitis. Methods: Clinical trials were identified in the published literature by using an electronic search strategy and were evaluated by using a risk of bias tool. Treatment outcome (symptom scores, medication scores, and combined symptom and medication scores) and provocation testing results (nasal provocation and skin-prick testing) were included in a meta-analysis of standardized mean difference with subgrouping by using a random-effects model. Overall adverse event rates were tabulated, and overall risk ratios were calculated by using a random-effects model. Results: We identified 17 clinical trials that met eligibility criteria. The standardized mean difference of ILIT on the symptom and medication score was ‐0.72 (95% confidence interval [CI], ‐0.98 to ‐0.46; p < 0.0001) (n = 10). The standardized mean difference of ILIT on nasal provocation and skin-prick testing was ‐1.00 (95% CI, ‐1.38 to ‐0.61; p < 0.0001) (n = 7) and ‐0.73 (95% CI, ‐0.99 to ‐0.47; p < 0.0001) (n = 7), respectively. No statistically significant heterogeneity was detected. The overall adverse event rate was 39.5% for ILIT and 23.5% for placebo. Also, 98.4% of adverse events were mild. Conclusion: Our meta-analysis demonstrated that ILIT was safe, conferred desensitization to seasonal and nonseasonal allergens, alleviated allergic rhinitis symptoms, and reduced medication use. A larger randomized, double-blind, placebo controlled trial will be necessary for wider adaptation of this form of AIT.

Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A systematic review and meta-analysis

2010 ◽  
Vol 126 (3) ◽  
pp. 558-566 ◽  
Author(s):  
Danilo Di Bona ◽  
Antonella Plaia ◽  
Valeria Scafidi ◽  
Maria Stefania Leto-Barone ◽  
Gabriele Di Lorenzo
Keyword(s):  
Systematic Review ◽  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Sublingual Immunotherapy ◽  
Meta Analysis

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison

2012 ◽  
Vol 130 (5) ◽  
pp. 1097-1107.e2 ◽  
Author(s):  
Danilo Di Bona ◽  
Antonella Plaia ◽  
Maria Stefania Leto-Barone ◽  
Simona La Piana ◽  
Gabriele Di Lorenzo
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Sublingual Immunotherapy ◽  
Meta Analysis

scholarly journals Sublingual immunotherapy for pollen allergic rhinitis: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Lufang Feng ◽  
Liujiao Cao ◽  
Peijing Yan ◽  
Xiajing Chu ◽  
Na Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Allergic Rhinitis ◽  
Adverse Events ◽  
Sublingual Immunotherapy ◽  
Meta Analysis ◽  
Gastrointestinal Symptoms ◽  
Specific Ige ◽  
Cochrane Library ◽  
Serious Adverse Events

Intro Allergic rhinitis（AR） is a common condition which can significantly impair quality of life. This study aimed to illustrate the efficacy and safety of sublingual immunotherapy (SLIT) on pollen AR patients. Methods Four electronic databases (PubMed, EMBASE, Cochrane Library, and Web of Science) were searched from their inception until September 2019. Two reviewers （FLF and CLJ） independently extracted the data. The Cochrane’s Risk of Bias tool was used to assess the quality of included studies. The outcomes of study were calculated by MD or SMD with 95%CI. A meta-analysis was performed using RevMan 5.3 software. Results In this systematic review, a total of 8 articles were included, involving 785 participants. The quality of the included studies ranged from low to moderate. The results of the meta-analysis showed that compared with placebo, a significant reduction of nasal symptoms were observed on SLIT (MD = −0.84, 95% CI = −1.47 to −0.22, P < 0.05), IgE (SMD =0.46, 95% CI = 0.16 to 0.76, P < 0.05); No significant effect on medication scores (MD = −0.41, 95% CI = −0.89 to 0.07, P =0.10). No serious adverse events were reported, and symptoms of adverse events were reported more frequently in the gastrointestinal symptoms. Conclusion SLIT can effectively relieve rhinitis symptoms and decrease the level of specific-IgE for pollen allergic rhinitis patients and the safety was verified. But due to the low quality of studies, more high-quality randomized trials are needed to provide stronger evidence of the conclusion.

scholarly journals Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

Allergy ◽  
2005 ◽  
Vol 60 (1) ◽  
pp. 4-12 ◽  
Author(s):  
D. R. Wilson ◽  
M. Torres Lima ◽  
S. R. Durham
Keyword(s):  
Systematic Review ◽  
Allergic Rhinitis ◽  
Sublingual Immunotherapy ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document